CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7005 result(s)

MRI-guided Focused Ultrasound for Treatment of Uterine Fibroids

Last Updated: July 11, 2005
Result type: Reports

Magnetic resonance imaging-guided focused ultrasound (MRI-FUS) is a minimally invasive alternative to surgical and less invasive treatments for uterine fibroids. Early results from small sample studies indicate that the procedure may provide short-term symptom relief with advantages such as shorter recovery time. Few occurrences of major adve...

Costs and Outcomes of Chiropractic Treatment for Low Back Pain

Last Updated: July 8, 2005
Result type: Reports

Technology Chiropractic treatment Disease Low back pain (LBP) is tiredness, discomfort or pain in the low back. It is experienced by 70% to 80% of adults at some time during their lives. In Canada, it is estimated that medical expenditure on LBP costs $6 billion to $12 billion annually. In addition, there are societal costs due to lost produc...

Pregabalin (Lyrica)

Last Updated: June 27, 2005
Result type: Reports
Product Line: Common Drug Review
Generic Name: Pregabalin
Indications: Pain, Neuropathic

  • Brand Name: Lyrica
  • Manufacturer: Pfizer Canada Inc.
  • Project Number: S0036
  • Project Status: Complete
  • Submission Type: New

Role of Combination Inhaled Corticosteroids and Long Acting Beta Agonists in the Treatment of Adult Asthma

Last Updated: June 17, 2005
Result type: Reports

An inhaled corticosteroid (ICS) and a long acting beta agonist (LABA) are combined in an inhaler for treatment of persistent asthma. There is evidence that maintenance therapy with a combination ICS/LABA inhaler improves clinical outcomes and reduces airflow obstruction in patients with persistent asthma, who are not well controlled even...

A Review of Guidelines for Referral of Patients to Sleep Laboratories

Last Updated: June 1, 2005
Result type: Reports

Disease or Condition Conditions include obstructive sleep apnea in adults and in children, other conditions that produce sleep disturbances, respiratory disorders, sudden infant death syndrome, insomnia, depression with insomnia, narcolepsy, parasomnias, restless legs syndrome and periodic limb movement disorder. Technology Description Patien...

Omalizumab (Xolair)

Last Updated: April 18, 2005
Result type: Reports
Product Line: Common Drug Review
Generic Name: Omalizumab
Indications: Asthma, severe persistent

  • Brand Name: Xolair
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: S0035
  • Project Status: Cancelled
  • Submission Type: New

Alemtuzumab for B-cell Chronic Lymphocytic Leukemia

Last Updated: March 31, 2005
Result type: Reports

Alemtuzumab, a humanized monoclonal antibody, is thought to destroy cancer cells through immune system stimulation or apoptosis induction (programmed cell death). In case series studies using alemtuzumab as salvage therapy, about a third of patients with B-cell chronic lymphocytic leukemia (B-CLL), who were otherwise refractory to chemothera...